KLRK1 and cancer: HDAC inhibitors (HDACi) such as valproic acid (VPA) and entinostat have been shown to sensitize NK cell-mediated killing by upregulating expression of NKG2D ligands MICA/B or ULBP1on cancer cells10, 11, 12, 13, 14, 15, suggesting that HDACi might have promising applications in cancer immunotherapy, especially in combination with adoptive NK cell therapy.